Contribution of circulating sclerostin and estradiol for inadequate response to bisphosphonate therapy in women with postmenopausal osteoporosis

2014 ◽  
Author(s):  
M Munoz-Torres ◽  
A Diez-Perez ◽  
J M Olmos ◽  
X Nogues ◽  
M Sosa ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Bisphosphonate Therapy ◽  
Inadequate Response

Comparative Efficacy of Alendronate upon Vertebral Bone Mineral Density and Fracture Rates in East Asians Versus Non-East Asians with Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 50 (10) ◽  
pp. 738-746 ◽  
Author(s):  
Yexin Wang ◽  
Gongwei Jia ◽  
Jin Song ◽  
Xiangqing Kong ◽  
Weihong Zhang ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Postmenopausal Osteoporosis ◽  
Meta Analysis ◽  
East Asian ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
East Asians ◽  
Vertebral Fracture Risk ◽  
Lumbar Spinal

AbstractBisphosphonates, such as alendronate, have become the most widely used and effective anti-resorptive therapy for postmenopausal osteoporosis. Previous genetic studies suggest that ethnicity may drive differing responses to bisphosphonate therapy in East Asians and non-East Asians. Therefore, the aim of this study was to comparatively evaluate the efficacy of alendronate upon lumbar spinal BMD and vertebral fracture rates in East Asians and non-East Asians with postmenopausal osteoporosis. MEDLINE, EMBASE, and Cochrane CENTRAL were searched for relevant randomized controlled trials (RCTs) comparing the efficacy of alendronate versus placebo (or calcium/mineral and/or Vitamin D or hormone replacement therapy) in primary postmenopausal osteoporotic women. We calculated the weighted mean differences (WMDs) for lumbar spinal BMD and the risk ratios (RRs) for vertebral fracture risk along with their respective 95% confidence intervals (CIs). From an initial set of 445 non-duplicate records, 13 full-text articles were finally included in this meta-analysis consisting of four East Asian RCTs and nine non-East Asian RCTs. Alendronate therapy displayed significant effects in improving lumbar spinal BMD in both East Asians [WMD (95% CI)=5.30 (0.32–10.29), p=0.037] and non-East Asians [WMD (95% CI)=5.73 (3.61–7.85), p=0.000]. Alendronate therapy did not display significant effects upon vertebral fracture risk in East Asians [RR (95% CI)=0.41 (0.06–2.73), p=0.358] but did display a significant effect upon lowering vertebral fracture risk in non-East Asians [RR (95% CI)=0.55 (0.42–0.72), p=0.000]. These findings suggest that ethnicity may affect the efficacy of bisphosphonate therapy in postmenopausal osteoporotic women.

Bisphosphonate therapy for the treatment of postmenopausal osteoporosis

Aging Health ◽  
2005 ◽  
Vol 1 (3) ◽  
pp. 459-474 ◽  
Author(s):  
Jean-Pierre Devogelaer ◽  
Yves Boutsen ◽  
Daniel H Manicourt
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Bisphosphonate Therapy

AB0622 Significance of body mass index for the effect of bisphosphonate therapy in women with postmenopausal osteoporosis

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A979.3-A980
Author(s):  
S. B. Milenkovic ◽  
A. N. Dimic ◽  
I. M. Aleksic ◽  
N. A. Dimic ◽  
S. Stojanovic ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Postmenopausal Osteoporosis ◽  
Body Mass ◽  
Bisphosphonate Therapy

scholarly journals Factors Associated With Inadequate Response to Bisphosphonate Therapy in Patients With Osteoporosis in Real-Life Clinical Practice: a Single-Center Retrospective Analysis of 300 Patients

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A245-A246
Author(s):  
Luciana Pinto Valadares ◽  
Bruno Silva de Araujo Ferreira ◽  
Bernardo Matos Cunha ◽  
Larissa Aniceto Moreira ◽  
Frederico Gideoni Albinati Batista ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Real Life ◽  
Bisphosphonate Therapy ◽  
Categorical Variables ◽  
Inadequate Response ◽  
Oral Bisphosphonates ◽  
Single Center ◽  
Mineral Density ◽  
Factors Associated

Abstract Introduction: Bone mineral density (BMD) measurement by dual X-ray absorptiometry (DXA) is a useful tool to monitor response to osteoporosis treatment in clinical practice. Despite bisphosphonates therapy, some patients may exhibit bone loss during treatment for different reasons. These patients may have greater fracture risk than responders and may have unrecognized secondary causes that require further attention and treatment. Objectives: To identify factors associated with inadequate response (IR) to bisphosphonates therapy in patients with osteoporosis in real-life clinical practice. Methods: This is a single-center case-control study of patients with osteoporosis treated with bisphosphonates as recommended. Baseline and follow-up (12–24 months/apart) DXA scans were performed on same device (GE-Lunar Prodigy). IR was defined as loss of BMD greater than the least significant change (LSC) on the follow-up DXA. Clinical, biochemical and densitometric parameters of patients with IR were compared to responders using t-test or Mann-Whitney test (continuous), or chi-square test (categorical variables), as appropriated. We used logistic regression to assess the association magnitude between exposures and IR. Results: From 300 patients included from 2014 to 2018 (13% males, mean age 68 ±10 years), 198(66%) were treated with oral bisphosphonates and 102(34%) with zoledronic acid (ZA). IR was observed in 44(15%) patients. All parameters were similar at baseline, except for greater prevalence of oral bisphosphonates (82% vs 63%, p=0.016) and anticonvulsants use (18% vs 7%, p=0.015) in patients with IR compared to responders. Additionally, patients with IR exhibited a lower % change in CTX following therapy in comparison to responders (median -37% [IQR -68; -16%] vs -57% [-74; -32], p=0.029, respectively), and higher serum CTX levels after treatment (median 236pg/mL [IQR 162; 344] vs 165pg/mL [119; 254], p=0.004). The likelihood of IR was greater with oral bisphosphonates then with ZA (OR 2.61, IC95% 1.16–5.81, p=0.002), and with anticonvulsants use (OR 2.94. IC95% 1.19–7.25, p=0.019). The association with IR persisted for both variables (p≤0.01), when accounted simultaneously in the same model, along with age and gender. Conclusion: Inadequate bisphosphonate response was present in 15% of individuals, which was independently associated with anticonvulsant use and particularly among those on oral bisphosphonate therapy rather than ZA. This knowledge may help to clinically identify potential modifiable factors related to unresponsiveness and to optimize treatment accordingly.

scholarly journals THE POSSIBLE INFLUENCE OF BISPHOSPHONATE THERAPY AND ITS COMBINATION WITH STATINS ON PARAMETERS OF AORTIC STIFFNESS IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

2014 ◽  
Vol 17 (3) ◽  
pp. 15-21
Author(s):  
I V Barinova ◽  
Z N Blankova ◽  
N S Aslanyan ◽  
F T Ageev ◽  
O Yu Ryabtseva ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Stiffness ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Aortic Stiffness ◽  
Systolic Arterial Pressure ◽  
Collagen Type I ◽  
Bisphosphonate Therapy ◽  
Hypolipidemic Effect ◽  
Type I

The study shows that addition of statins to osteoporotic therapy in postmenopausal women with different cardiovascular risk beside desired hypolipidemic effect and reduction of arterial stiffness also elevates BMD at femoral neck by 4,9% from the baseline (p<0.05). Bisphosphonates therapy in postmenopausal women gives additional reduction of central systolic arterial pressure of 4.1 mm Hg with the tendency to improvement in the arterial stiffness. The dynamics of aortal stiffness was correlated with changers in intensity of bone remodeling (for N-terminal propeptides of type I procollagen (P1NP) p =0.47, p=0.019; for carboxyl-terminal telopeptide of collagen type I (CITP1) p=0.40, p=0.05) as well as systolic blood pressure (r=0.52, p=0.008). Conclusions. Bisphosphonate therapy and its combination with statins may influence the on parameters of blood pressure and aortic stiffness in women with postmenopausal osteoporosis.

Bisphosphonate Therapy for Postmenopausal Osteoporosis

1992 ◽  
Vol 85 (Supplement) ◽  
pp. 2S-31 ◽  
Author(s):  
NELSON B. WATTS
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Bisphosphonate Therapy
Sign in / Sign up

Export Citation Format

Share Document